- Home
- REBN vs MDCX Comparison
REBN vs MDCX Comparison
Compare REBN & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REBN | MDCX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 16.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | REBN | MDCX |
|---|---|---|
| Price | $2.02 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 30.5K | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $1.36 | $0.25 |
| 52 Week High | $3.40 | $3.69 |
Technical Indicators
Market Signals| Indicator | REBN | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 58.76 |
| Support Level | $1.81 | $0.38 |
| Resistance Level | $2.15 | $0.52 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 2.22 | 97.89 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.